

A Urine-Based Test to Detect Recurrence during the Follow-up of Non-Muscle Invasive Bladder Cancer (NMIBC)



Simple & Fast

- Performed from a simple urine sample
- The result was obtained within a 24-hour period.

Test description

- Ready-to-use Urodiag Multiplex PCR Kit
- Genetic and epigenetic analysis
- Simultaneous identification of mutations and DNA methylated markers
- Analysis using multiplex quantitative real-time PCR
- Urodiag software for rendering results



Clinical Performance



	High-risk tumours	Low-risk tumours
Sensitivity	97%	93%
NPV	99%	98%

Clinical Benefit

- Non-invasive test
- High accuracy in detecting NMIBC recurrence
- Significantly reduces the number of follow-up cystoscopies
- Strongly improves patient comfort
- Suitable in clinical laboratories
- Replaces cytology

Patent

WO/2015/075027: Methods for the surveillance, diagnosis and screening of bladder cancer

Publications

BMC Med Genet. 2020. doi: 10.1186/s12881-020-01050-w.

BMC Cancer. 2016. doi: 10.1186/s12885-016-2748-5.